Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sipai Health Technology Co's Debt-to-Equity or its related term are showing as below:
FRA:AX1'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.07 Med: 0.02 Max: 0.04
Current: 0.02
During the past 7 years, the highest Debt-to-Equity Ratio of Sipai Health Technology Co was 0.04. The lowest was -0.07. And the median was 0.02.
FRA:AX1's Debt-to-Equity is ranked better than 96.97% of 99
companies
in the Medical Distribution industry
Industry Median: 0.48
vs FRA:AX1: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sipai Health Technology Co Debt-to-Equity Related Terms
Sipai Health Technology Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AX1 vs MCK, COR, CAH: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Sipai Health Technology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sipai Health Technology Co Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sipai Health Technology Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sipai Health Technology Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sipai Health Technology Co (FRA:AX1) has a Debt-to-Equity of 0.02 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sipai Health Technology Co and its competitors. This is near median its historical median of 0.02. According to the industry distribution chart, Sipai Health Technology Co ranks #3 out of 99 companies in the Medical Distribution industry, placing it in the top 3%.
Is Sipai Health Technology Co's Debt-to-Equity too high?
Sipai Health Technology Co's current Debt-to-Equity of 0.02 is near median its 10-year median of 0.02. The Medical Distribution industry median Debt-to-Equity is 0.48. Sipai Health Technology Co's value of 0.02 is 95.8% below this industry median. Based on the distribution chart, Sipai Health Technology Co ranks #3 out of 99 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sipai Health Technology Co has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Sipai Health Technology Co's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sipai Health Technology Co ranks #3 out of 99 companies for Debt-to-Equity. This places Sipai Health Technology Co in the top 3% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.48. Sipai Health Technology Co's value of 0.02 is 95.8% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.48, Sipai Health Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sipai Health Technology Co's current Debt-to-Equity of 0.02 is 95.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sipai Health Technology Co and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sipai Health Technology Co's current Debt-to-Equity is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sipai Health Technology Co stock overvalued right now?
Sipai Health Technology Co (FRA:AX1) has a current Debt-to-Equity of 0.02. The stock's GF Value™ is €0.22, compared to a current price of €0.14 — trading 36.8% below its estimated fair value. The current Debt-to-Equity is 0.02, which is near median its 10-year median of 0.02 and 95.8% below the Medical Distribution industry median of 0.48. Sipai Health Technology Co's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sipai Health Technology Co (FRA:AX1), the current Debt-to-Equity is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sipai Health Technology Co (FRA:AX1) Overvalued in 2026?
Based on GuruFocus' analysis, Sipai Health Technology Co stock appears to be undervalued.
The current stock price of €0.14 is trading 36.8% below its estimated GF Value™ of €0.22.
Key valuation signals for FRA:AX1:
Debt-to-Equity: 0.02 (near median its 10-year median of 0.02)
GF Value™: €0.22 vs. price of €0.14 (36.8% below fair value)
Industry Position: 95.8% below the Medical Distribution median (#3 of 99)
No single metric tells the full story. See the FRA:AX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sipai Health Technology Co Ltd is a medical technology and health management company in China. The company has three reportable operating segments: Specialty Pharmacy Business - engaged in the operation and distribution of specialty pharmacy stores and pharmaceutical products; Physician Research Assistance Business - offering pharmaceutical companies and other clinical trial institutions site management organization services; Commercial Insurance Services Business - rendering insurance brokerage services to insurance companies and health management services to insurance carriers and enterprise clients. The company generates key revenue from the Specialty Pharmacy Business. Almost all of the company's revenues were derived from operations in the PRC.
64GF Score
Get the complete analysis for FRA:AX1
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX1 has been successfully added to your 
